Symbols / TLSA Stock $1.24 +0.81% Tiziana Life Sciences Ltd
TLSA (Stock) Chart
About
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Stock Fundamentals
Scroll to Statements| Market Cap | 157.79M | Enterprise Value | 140.20M | Income | -12.84M | Sales | — | Book/sh | 0.08 | Cash/sh | 0.06 |
| Dividend Yield | — | Payout | 0.00% | Employees | 9 | IPO | — | P/E | — | Forward P/E | -6.20 |
| PEG | — | P/S | — | P/B | 16.10 | P/C | — | EV/EBITDA | -7.59 | EV/Sales | — |
| Quick Ratio | 1.65 | Current Ratio | 1.72 | Debt/Eq | 1.16 | LT Debt/Eq | — | EPS (ttm) | -0.12 | EPS next Y | -0.20 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2022-12-27 | ROA | -83.78% | ROE | -232.31% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 127.25M | Shs Float | 64.81M | Short Float | 1.71% |
| Short Ratio | 10.02 | Short Interest | — | 52W High | 2.60 | 52W Low | 1.14 | Beta | 0.37 | Avg Volume | 158.22K |
| Volume | 94.60K | Target Price | $8.00 | Recom | None | Prev Close | $1.23 | Price | $1.24 | Change | 0.81% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2022-06-13 | init | ThinkEquity | — → Buy | $4 |
- Tesla Q1 Preview: Losing The Robotics Race - Seeking Alpha Mon, 20 Apr 2026 22
- A J.P. Morgan analyst sees 60% downside to Tesla stock—and he may be too optimistic - Fortune ue, 07 Apr 2026 07
- Tiziana Life Sciences (Nasdaq: TLSA) to spin out IL-6 asset into new listed company - Stock Titan ue, 02 Dec 2025 08
- While insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownership - Yahoo Finance Mon, 09 Feb 2026 08
- Tiziana (TLSA) Stock Large Cap Focus (Hovering) 2026-04-16 - Most Discussed Stocks - Cổng thông tin điện tử Tỉnh Sơn La hu, 16 Apr 2026 21
- Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab - Quiver Quantitative Mon, 15 Dec 2025 08
- Tiziana Life Sciences (TLSA) Unveils Promising Preclinical Findi - GuruFocus hu, 16 Apr 2026 17
- Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum - Benzinga Wed, 01 Apr 2026 07
- Tesla’s Business Is at a Historic Crossroads, but What About Its Stock Price? - inkl Wed, 22 Apr 2026 13
- CEO backs $17.6M Tiziana raise to fund key na-SPMS and MSA trials - Stock Titan Fri, 16 Jan 2026 08
- Tiziana Life Sciences Announces $8 Million Registered Direct Offering of Ordinary Shares to Support Clinical Trials - Quiver Quantitative Fri, 16 Jan 2026 08
- TSLA: Should You 'Buy' or 'Sell' Tesla Stock in 2026? - Yahoo Finance Fri, 02 Jan 2026 08
- New nasal treatment calms brain immune activity in progressive MS patients - Stock Titan Wed, 25 Feb 2026 08
- TSLA Stock Price Prediction: Where Tesla Could Be by 2025, 2026, 2030 - Yahoo Finance Fri, 19 Dec 2025 08
- Tiziana leaders invest in $8.8M raise to finish Phase 2 na-SPMS, MSA trials - Stock Titan Fri, 16 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
—
|
—
|
—
|
0.00
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
0.00
|
| Gross Profit |
|
—
|
—
|
—
|
0.00
|
| Operating Expense |
|
15.79
-12.18%
|
17.98
+23.30%
|
14.59
-46.72%
|
27.37
|
| Research And Development |
|
5.23
-35.55%
|
8.11
-37.38%
|
12.96
-1.92%
|
13.21
|
| Selling General And Administration |
|
—
|
0.00
|
0.00
-100.00%
|
0.85
|
| General And Administrative Expense |
|
—
|
—
|
—
|
0.85
|
| Salaries And Wages |
|
—
|
0.00
|
0.00
-100.00%
|
0.85
|
| Other Operating Expenses |
|
10.56
+7.03%
|
9.87
+505.21%
|
1.63
-87.75%
|
13.31
|
| Total Expenses |
|
15.79
-12.18%
|
17.98
+23.30%
|
14.59
-46.72%
|
27.37
|
| Operating Income |
|
-15.79
+12.18%
|
-17.98
-23.30%
|
-14.59
+46.72%
|
-27.37
|
| Total Operating Income As Reported |
|
-15.79
+12.18%
|
-17.98
-23.30%
|
-14.59
+46.72%
|
-27.37
|
| EBITDA |
|
-16.62
+3.03%
|
-17.14
-11.94%
|
-15.31
+41.88%
|
-26.34
|
| Normalized EBITDA |
|
-14.86
+11.22%
|
-16.73
-15.89%
|
-14.44
+45.18%
|
-26.34
|
| Reconciled Depreciation |
|
0.12
+29.17%
|
0.10
+88.24%
|
0.05
-63.83%
|
0.14
|
| EBIT |
|
-16.74
+2.86%
|
-17.23
-12.19%
|
-15.36
+42.00%
|
-26.48
|
| Total Unusual Items |
|
-1.76
-337.81%
|
-0.40
+53.74%
|
-0.87
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-1.76
-337.81%
|
-0.40
+53.74%
|
-0.87
|
0.00
|
| Special Income Charges |
|
—
|
—
|
0.00
|
0.00
|
| Write Off |
|
—
|
—
|
0.00
|
0.00
|
| Net Income |
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
+34.25%
|
-23.42
|
| Pretax Income |
|
-16.75
+2.88%
|
-17.24
-11.98%
|
-15.40
+42.24%
|
-26.66
|
| Net Non Operating Interest Income Expense |
|
0.81
-29.37%
|
1.14
+19166.67%
|
-0.01
+96.59%
|
-0.18
|
| Interest Expense Non Operating |
|
0.01
-40.00%
|
0.01
-73.68%
|
0.04
-78.41%
|
0.18
|
| Net Interest Income |
|
0.81
-29.37%
|
1.14
+19166.67%
|
-0.01
+96.59%
|
-0.18
|
| Interest Expense |
|
0.01
-40.00%
|
0.01
-73.68%
|
0.04
-78.41%
|
0.18
|
| Interest Income Non Operating |
|
0.81
-29.46%
|
1.15
+3506.25%
|
0.03
|
0.00
|
| Interest Income |
|
0.81
-29.46%
|
1.15
+3506.25%
|
0.03
|
0.00
|
| Other Income Expense |
|
-1.76
-337.81%
|
-0.40
+50.00%
|
-0.80
-190.03%
|
0.89
|
| Other Non Operating Income Expenses |
|
—
|
—
|
0.07
-92.72%
|
0.89
|
| Gain On Sale Of Security |
|
-1.76
-337.81%
|
-0.40
+53.74%
|
-0.87
|
—
|
| Tax Provision |
|
-4.88
-1187.53%
|
0.45
|
0.00
+100.00%
|
-3.24
|
| Tax Rate For Calcs |
|
0.00
+38.85%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.51
-507.92%
|
-0.08
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
+34.25%
|
-23.42
|
| Net Income From Continuing Operation Net Minority Interest |
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
+34.25%
|
-23.42
|
| Net Income From Continuing And Discontinued Operation |
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
+34.25%
|
-23.42
|
| Net Income Continuous Operations |
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
+34.25%
|
-23.42
|
| Normalized Income |
|
-10.62
+38.89%
|
-17.37
-19.59%
|
-14.53
+37.96%
|
-23.42
|
| Net Income Common Stockholders |
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
+34.25%
|
-23.42
|
| Diluted EPS |
|
-0.11
+35.29%
|
-0.17
-13.33%
|
-0.15
+37.50%
|
-0.24
|
| Basic EPS |
|
-0.11
+35.29%
|
-0.17
-13.33%
|
-0.15
+37.50%
|
-0.24
|
| Basic Average Shares |
|
106.67
+4.10%
|
102.47
+0.93%
|
101.53
+3.67%
|
97.93
|
| Diluted Average Shares |
|
106.67
+4.10%
|
102.47
+0.93%
|
101.53
+3.67%
|
97.93
|
| Diluted NI Availto Com Stockholders |
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
+34.25%
|
-23.42
|
| Gain On Sale Of PPE |
|
—
|
—
|
0.00
|
0.00
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets |
|
11.28
-7.39%
|
12.18
-53.98%
|
26.48
|
| Current Assets |
|
7.51
+2.33%
|
7.34
-69.78%
|
24.28
|
| Cash Cash Equivalents And Short Term Investments |
|
3.72
+214.79%
|
1.18
-93.47%
|
18.12
|
| Cash And Cash Equivalents |
|
3.72
+214.79%
|
1.18
-93.47%
|
18.12
|
| Receivables |
|
3.69
-39.00%
|
6.05
+1.04%
|
5.99
|
| Other Receivables |
|
0.05
-56.20%
|
0.12
-6.92%
|
0.13
|
| Taxes Receivable |
|
0.03
-99.16%
|
3.79
-10.67%
|
4.25
|
| Prepaid Assets |
|
0.09
-9.80%
|
0.10
-40.00%
|
0.17
|
| Hedging Assets Current |
|
—
|
—
|
—
|
| Total Non Current Assets |
|
3.78
-22.10%
|
4.85
+120.82%
|
2.19
|
| Net PPE |
|
0.19
-36.18%
|
0.29
-24.68%
|
0.39
|
| Gross PPE |
|
0.19
-36.18%
|
0.29
-24.68%
|
0.39
|
| Accumulated Depreciation |
|
—
|
—
|
—
|
| Machinery Furniture Equipment |
|
—
|
—
|
—
|
| Other Properties |
|
0.19
-36.18%
|
0.29
-24.68%
|
0.39
|
| Goodwill And Other Intangible Assets |
|
—
|
0.00
|
0.00
|
| Investments And Advances |
|
3.59
-21.19%
|
4.55
+152.16%
|
1.81
|
| Long Term Equity Investment |
|
3.59
-21.19%
|
4.55
+152.16%
|
1.81
|
| Non Current Accounts Receivable |
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
7.35
+10.53%
|
6.65
-3.74%
|
6.91
|
| Current Liabilities |
|
7.35
+12.37%
|
6.54
-1.86%
|
6.66
|
| Payables And Accrued Expenses |
|
7.23
+13.20%
|
6.39
-2.22%
|
6.53
|
| Payables |
|
5.58
+34.88%
|
4.14
-16.63%
|
4.96
|
| Accounts Payable |
|
5.58
+34.88%
|
4.14
-16.63%
|
4.96
|
| Current Accrued Expenses |
|
1.65
-26.67%
|
2.25
+43.31%
|
1.57
|
| Current Debt And Capital Lease Obligation |
|
0.11
-23.19%
|
0.14
+13.11%
|
0.12
|
| Current Capital Lease Obligation |
|
0.11
-23.19%
|
0.14
+13.11%
|
0.12
|
| Other Current Liabilities |
|
0.01
-14.29%
|
0.01
+55.56%
|
0.01
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
0.11
-55.14%
|
0.24
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
0.11
-55.14%
|
0.24
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.11
-55.14%
|
0.24
|
| Stockholders Equity |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Common Stock Equity |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Capital Stock |
|
0.11
+7.77%
|
0.10
+0.98%
|
0.10
|
| Common Stock |
|
0.11
+7.77%
|
0.10
+0.98%
|
0.10
|
| Share Issued |
|
111.46
+8.12%
|
103.09
+0.80%
|
102.27
|
| Ordinary Shares Number |
|
111.46
+9.80%
|
101.51
+0.92%
|
100.59
|
| Treasury Shares Number |
|
0.00
-100.00%
|
1.57
-6.54%
|
1.68
|
| Additional Paid In Capital |
|
23.11
+40.10%
|
16.49
+5.75%
|
15.60
|
| Retained Earnings |
|
-144.83
-8.34%
|
-133.68
-14.98%
|
-116.26
|
| Gains Losses Not Affecting Retained Earnings |
|
116.99
-0.06%
|
117.06
+1.29%
|
115.57
|
| Treasury Stock |
|
0.00
-100.00%
|
1.57
+19.24%
|
1.32
|
| Other Equity Adjustments |
|
118.70
+0.00%
|
118.70
+0.00%
|
118.70
|
| Total Equity Gross Minority Interest |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Total Capitalization |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Working Capital |
|
0.16
-79.95%
|
0.80
-95.47%
|
17.62
|
| Invested Capital |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Total Debt |
|
0.11
-57.09%
|
0.25
-32.33%
|
0.36
|
| Capital Lease Obligations |
|
0.11
-57.09%
|
0.25
-32.33%
|
0.36
|
| Net Tangible Assets |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Tangible Book Value |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Duefrom Related Parties Current |
|
3.61
+68.71%
|
2.14
+32.47%
|
1.61
|
| Dueto Related Parties Current |
|
—
|
—
|
0.00
|
| Foreign Currency Translation Adjustments |
|
-1.71
-4.34%
|
-1.64
+47.70%
|
-3.13
|
| Other Equity Interest |
|
8.56
+20.07%
|
7.13
+21.11%
|
5.89
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-1.53
+90.28%
|
-15.70
+19.97%
|
-19.61
+9.87%
|
-21.76
|
| Cash Flow From Continuing Operating Activities |
|
-1.53
+90.28%
|
-15.70
+19.97%
|
-19.61
+9.87%
|
-21.76
|
| Net Income From Continuing Operations |
|
-16.75
+2.88%
|
-17.24
-11.98%
|
-15.40
+42.24%
|
-26.66
|
| Depreciation Amortization Depletion |
|
0.12
+29.17%
|
0.10
+88.24%
|
0.05
-63.83%
|
0.14
|
| Depreciation |
|
0.12
+29.17%
|
0.10
+88.24%
|
0.05
-63.83%
|
0.14
|
| Depreciation And Amortization |
|
0.12
+29.17%
|
0.10
+88.24%
|
0.05
-63.83%
|
0.14
|
| Other Non Cash Items |
|
3.52
+662.56%
|
-0.62
|
—
|
0.87
|
| Stock Based Compensation |
|
1.43
-17.59%
|
1.73
+222.98%
|
-1.41
-127.26%
|
5.17
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
|
0.00
|
| Operating Gains Losses |
|
0.16
-89.53%
|
1.52
+149.74%
|
-3.05
-58.48%
|
-1.93
|
| Unrealized Gain Loss On Investment Securities |
|
1.76
+337.81%
|
0.40
-53.74%
|
0.87
|
0.00
|
| Net Foreign Currency Exchange Gain Loss |
|
0.16
-89.60%
|
1.52
+147.72%
|
-3.18
-67.61%
|
-1.90
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
|
0.00
+100.00%
|
-0.03
|
| Change In Working Capital |
|
-0.55
+65.11%
|
-1.58
-35.91%
|
-1.16
-50.58%
|
-0.77
|
| Change In Receivables |
|
-1.47
+3.61%
|
-1.52
-31.61%
|
-1.16
-1215.91%
|
-0.09
|
| Change In Payables And Accrued Expense |
|
0.00
|
0.00
+100.00%
|
-1.35
-97.81%
|
-0.69
|
| Change In Payable |
|
—
|
—
|
-1.35
-97.81%
|
-0.69
|
| Change In Account Payable |
|
0.00
|
0.00
+100.00%
|
-1.35
-97.81%
|
-0.69
|
| Change In Other Current Assets |
|
0.08
-2.50%
|
0.08
-92.02%
|
1.00
+94.19%
|
0.52
|
| Change In Other Current Liabilities |
|
0.84
+707.97%
|
-0.14
-139.77%
|
0.35
+167.25%
|
-0.52
|
| Investing Cash Flow |
|
-0.07
+94.33%
|
-1.25
+68.64%
|
-4.00
-3173.85%
|
0.13
|
| Cash Flow From Continuing Investing Activities |
|
-0.07
+94.33%
|
-1.25
+68.64%
|
-4.00
-3173.85%
|
0.13
|
| Net PPE Purchase And Sale |
|
-0.02
|
0.00
|
0.00
+100.00%
|
-0.02
|
| Purchase Of PPE |
|
-0.02
|
0.00
|
0.00
+100.00%
|
-0.02
|
| Capital Expenditure |
|
-0.02
|
—
|
—
|
-0.02
|
| Net Investment Purchase And Sale |
|
-0.05
+95.85%
|
-1.25
+68.64%
|
-4.00
|
0.00
|
| Purchase Of Investment |
|
-0.05
+95.85%
|
-1.25
+68.64%
|
-4.00
|
0.00
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
0.15
|
| Financing Cash Flow |
|
4.50
+11162.50%
|
0.04
+172.73%
|
-0.06
-139.13%
|
-0.02
|
| Cash Flow From Continuing Financing Activities |
|
4.50
+11162.50%
|
0.04
+172.73%
|
-0.06
-139.13%
|
-0.02
|
| Net Issuance Payments Of Debt |
|
-0.14
-18.49%
|
-0.12
-116.36%
|
-0.06
+63.82%
|
-0.15
|
| Issuance Of Debt |
|
—
|
—
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-0.14
-18.49%
|
-0.12
-116.36%
|
-0.06
+63.82%
|
-0.15
|
| Long Term Debt Payments |
|
-0.14
-18.49%
|
-0.12
-116.36%
|
-0.06
+63.82%
|
-0.15
|
| Net Long Term Debt Issuance |
|
-0.14
-18.49%
|
-0.12
-116.36%
|
-0.06
+63.82%
|
-0.15
|
| Short Term Debt Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
4.57
+18945.83%
|
0.02
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.07
-44.44%
|
0.14
|
0.00
-100.00%
|
0.13
|
| Changes In Cash |
|
2.91
+117.20%
|
-16.91
+28.54%
|
-23.67
-9.29%
|
-21.66
|
| Effect Of Exchange Rate Changes |
|
-0.37
-1210.71%
|
-0.03
+92.96%
|
-0.40
+79.93%
|
-1.98
|
| End Cash Position |
|
3.72
+214.79%
|
1.18
-93.47%
|
18.12
-57.04%
|
42.19
|
| Free Cash Flow |
|
-1.54
+90.16%
|
-15.70
+19.97%
|
-19.61
+9.96%
|
-21.78
|
| Common Stock Issuance |
|
4.57
+18945.83%
|
0.02
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
4.57
+18945.83%
|
0.02
|
0.00
|
0.00
|
| Taxes Refund Paid |
|
8.78
|
0.00
-100.00%
|
0.49
-65.37%
|
1.42
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|